Upgrades:
Sanofi (NASDAQ:SNY) was upgraded by SVB Leerink from a “market perform” rating to an “outperform” rating in a report issued on Monday, Analyst Price Targets reports.
Several other equities research analysts have also recently
weighed in on SNY. JPMorgan Chase & Co. reiterated an “overweight” rating
on shares of Sanofi in a report on Friday, July 30th. Morgan Stanley reissued
an “overweight” rating on shares of Sanofi in a report on Friday, August 6th.
Finally, UBS Group reiterated a “buy” rating on shares of Sanofi in a research
report on Thursday, August 12th. One equities research analyst has rated the
stock with a sell rating, two have given a hold rating and six have assigned a
buy rating to the stock. According to MarketBeat.com, the stock has an average
rating of “Buy” and an average price target of $53.00. Read
more …
The Western Union (NYSE:WU) was upgraded by equities researchers at Citigroup from a “neutral” rating to a “buy” rating in a report issued on Monday, The Fly reports.
NYSE WU opened at $20.23 on Monday. The stock has a fifty
day moving average of $21.94 and a 200-day moving average of $23.70. The stock
has a market capitalization of $8.22 billion, a P/E ratio of 10.32 and a beta
of 0.99. The Western Union has a 52 week low of $19.07 and a 52 week high of
$26.61. The company has a debt-to-equity ratio of 10.47, a quick ratio of 0.94
and a current ratio of 0.94. Read
more …
Eli Lilly and (NYSE:LLY) was upgraded by equities researchers at Citigroup from a "neutral" rating to a "buy" rating in a note issued to investors on Wednesday, The Fly reports. The brokerage presently has a $265.00 price target on the stock, up from their prior price target of $210.00. Citigroup's price objective indicates a potential upside of 19.58% from the company's current price. The analysts noted that the move was a valuation call.
LLY has been the topic of several other research reports.
Barclays upped their target price on shares of Eli Lilly and from $227.00 to
$250.00 and gave the stock an "overweight" rating in a research note
on Tuesday, July 6th. The Goldman Sachs Group upped their target price on
shares of Eli Lilly and from $252.00 to $270.00 and gave the stock a
"conviction-buy" rating in a research note on Monday, June 14th.
Cantor Fitzgerald increased their price objective on shares of Eli Lilly and
from $245.00 to $300.00 and gave the company an "overweight" rating
in a research report on Thursday, June 24th. Read
more …
UBS Group (NYSE:UBS) was upgraded by research analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating in a report issued on Wednesday, The Fly reports.
Other research analysts also recently issued reports about
the company. Credit Suisse Group reaffirmed an "outperform" rating on
shares of UBS Group in a report on Wednesday, July 21st. Morgan Stanley
reaffirmed a "hold" rating on shares of UBS Group in a report on
Tuesday, August 10th. Barclays reaffirmed an "underweight" rating on
shares of UBS Group in a report on Monday, July 19th. JPMorgan Chase & Co.
reaffirmed an "overweight" rating on shares of UBS Group in a report
on Wednesday, July 21st. Finally, The Goldman Sachs Group set a $15.80 target
price on UBS Group and gave the stock a "hold" rating in a report on
Thursday, July 22nd. One research analyst has rated the stock with a sell
rating, three have assigned a hold rating and ten have assigned a buy rating to
the stock. Based on data from MarketBeat.com, the stock has an average rating
of "Buy" and a consensus target price of $15.70. Read
more …
























































